Drug information provided by: Merative, Micromedex®
Umbralisib is used to treat marginal zone lymphoma (MZL) that has come back (relapsed) or did not respond to the treatment (refractory) in patients who have received at least one previous treatment (eg, anti-CD20-based treatment). It is also used to treat follicular lymphoma (FL) that has come back or did not respond to treatment in patients who have received at least 3 previous treatments.
This medicine is available only with your doctor's prescription.
This medicine was withdrawn from the U.S. market on June 1, 2022, due to safety concerns.
Portions of this document last updated: Feb. 01, 2024
Copyright: © Merative US L.P. 1973, 2024. All rights reserved. Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Make your tax-deductible gift and be a part of the cutting-edge research and care that's changing medicine.